| Followers | 3 |
| Posts | 297 |
| Boards Moderated | 0 |
| Alias Born | 01/20/2024 |
Friday, February 14, 2025 1:42:06 PM
TO move from the over-the-counter (OTC) market to Nasdaq, a company must meet financial and regulatory requirements. These include:
Shareholders: At least 550 shareholders must own 1.25 million public shares
Trading volume: The stock must have a minimum average daily trading volume of 2,000 shares over the 30 trading days before listing
Price: The stock must be listed at a price of at least $4 per share
Cash flow: The company must have had a cash flow of at least $27.5 million in the last three fiscal years
Earnings: The company must have had pre-tax earnings of at least $11 million in the previous three years
The process for moving from the OTC market to Nasdaq includes:
Filling out an application
Providing financial statements
Getting approved for listing by Nasdaq
The application process typically takes four to six weeks, but can be shorter if the application doesn't have issues and the company responds quickly to comments.
Depending on the circumstances, the stock symbol may change.
THIS CAME FROM GOOGLE AI
glta
Shareholders: At least 550 shareholders must own 1.25 million public shares
Trading volume: The stock must have a minimum average daily trading volume of 2,000 shares over the 30 trading days before listing
Price: The stock must be listed at a price of at least $4 per share
Cash flow: The company must have had a cash flow of at least $27.5 million in the last three fiscal years
Earnings: The company must have had pre-tax earnings of at least $11 million in the previous three years
The process for moving from the OTC market to Nasdaq includes:
Filling out an application
Providing financial statements
Getting approved for listing by Nasdaq
The application process typically takes four to six weeks, but can be shorter if the application doesn't have issues and the company responds quickly to comments.
Depending on the circumstances, the stock symbol may change.
THIS CAME FROM GOOGLE AI
glta
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
